BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 18617887)

  • 1. The adult human brain in preclinical drug development.
    Dragunow M
    Nat Rev Drug Discov; 2008 Aug; 7(8):659-66. PubMed ID: 18617887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection and enhancement of neurite outgrowth with small molecular weight compounds from screens of chemical libraries.
    Dwyer DS; Dickson A
    Int Rev Neurobiol; 2007; 77():247-89. PubMed ID: 17178477
    [No Abstract]   [Full Text] [Related]  

  • 3. From chemical to drug: neurodegeneration drug screening and the ethics of clinical trials.
    Heemskerk J; Tobin AJ; Ravina B
    Nat Neurosci; 2002 Nov; 5 Suppl():1027-9. PubMed ID: 12403977
    [No Abstract]   [Full Text] [Related]  

  • 4. Discovery of a new drug--from target identification to ultra-high-throughput screening.
    Golz S; Hüser J
    Clin Lab; 2007; 53(1-2):77-9. PubMed ID: 17323829
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved early clinical development through human microdosing studies.
    Wilding IR; Bell JA
    Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
    [No Abstract]   [Full Text] [Related]  

  • 6. Preclinical drug discovery research and training at Vanderbilt.
    Lindsley CW; Weaver D; Jones C; Marnett L; Conn PJ
    ACS Chem Biol; 2007 Jan; 2(1):17-20. PubMed ID: 17243778
    [No Abstract]   [Full Text] [Related]  

  • 7. Fragment-based drug design: combining philosophy with technology.
    Bartoli S; Fincham CI; Fattori D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue microarrays in drug discovery.
    Sauter G; Simon R; Hillan K
    Nat Rev Drug Discov; 2003 Dec; 2(12):962-72. PubMed ID: 14654795
    [No Abstract]   [Full Text] [Related]  

  • 9. Integrated assessment of preclinical data: shifting high attrition rates to earlier phase drug development.
    Korstanje C
    Curr Opin Investig Drugs; 2003 May; 4(5):519-21. PubMed ID: 12833643
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug development. Biotech thinking comes to academic medical centers.
    Alper J
    Science; 2003 Feb; 299(5611):1303-5. PubMed ID: 12610271
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
    Petersen TK
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening the receptorome: an efficient approach for drug discovery and target validation.
    Strachan RT; Ferrara G; Roth BL
    Drug Discov Today; 2006 Aug; 11(15-16):708-16. PubMed ID: 16846798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies.
    Kraemer B; Schellenberg GD
    Int Rev Neurobiol; 2007; 77():219-46. PubMed ID: 17178476
    [No Abstract]   [Full Text] [Related]  

  • 14. Screening for content--the evolution of high throughput.
    Dove A
    Nat Biotechnol; 2003 Aug; 21(8):859-64. PubMed ID: 12894197
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of high-content analysis for compound screening and target selection.
    Rausch O
    IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multipotent antioxidants: from screening to design.
    Zhang HY; Yang DP; Tang GY
    Drug Discov Today; 2006 Aug; 11(15-16):749-54. PubMed ID: 16846803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical and clinical development of immunocytokines.
    Sondel PM; Hank JA; Gan J; Neal Z; Albertini MR
    Curr Opin Investig Drugs; 2003 Jun; 4(6):696-700. PubMed ID: 12901228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invertebrate animal models of diseases as screening tools in drug discovery.
    Ségalat L
    ACS Chem Biol; 2007 Apr; 2(4):231-6. PubMed ID: 17455900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of drug safety testing: expanding the view and narrowing the focus.
    Stevens JL; Baker TK
    Drug Discov Today; 2009 Feb; 14(3-4):162-7. PubMed ID: 19100337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.